Siponimod (Mayzent, Novartis) had a sustained effect on slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS), according to new long-term data from a phase 3 study.
The guidelines provide clinical recommendations to providers treating patients with coronavirus disease 2019 (COVID-19).
The study examined the effects of unprotected, prolonged patient contact, along with certain exposures, on the risk of health care providers becoming infected with COVID-19.
Investigators used simulation models to project the transmission dynamics of COVID-19.
Insulin manufacturers are expanding insulin affordability options for patients with diabetes during the coronavirus pandemic.
A recent meta-analysis showed an association between regular aspirin use and reduced risk of developing several cancers of the digestive tract.
From drug information to patient education, these apps can help you be better at everything that you do.
President Trump's coronavirus task force urged to tap into the potential of community pharmacies in combatting the coronavirus pandemic.
Strategies for seizing revenue opportunities outside of the PBM.
Boost your financial IQ with these tips on how to manage your budget and increase cash flow.